Last Updated: 16/06/2015
Optimising antimalarial combination therapies in an area coendemic for vivax and falciparum malaria
Objectives
Previous studies led to a district-wide (population 180,000) change in policy for uncomplicated malaria to artemisinin combination therapy in 2006. The current proposal will expand our research agenda to address the next phase of ACT deployment, notably an understanding of the co-factors that determine its impact and cost-effectiveness and how these differentially affect P. falciparum and P. vivax. Novel and complementary studies are planned to optimise the treatment of vivax relapses, improve the diagnosis of G6PD deficiency and develop genetic tools for monitoring drug resistance.
University of Oxford, United Kingdom
Wellcome Sanger Institute, United Kingdom
The leading researcher of the project has established a large network of researchers, service providers, and policymakers in Papua, Indonesia to undertake a series of epidemiological, clinical, and laboratory studies to optimise the treatment and prevention of malaria.
This research will provide the evidence base upon which to optimise malaria control programmes. The crucial involvement of collaborative partners in the District Health Authority, local government and Indonesian National CDC will ensure that the results of the project impact directly on MoH policy decisions not only for Papua but also elsewhere in Indonesia.
The objective is that these tools will be endorsed by WHO and adopted by the current global elimination efforts.
Aug 2010 — Jul 2015
$2.12M
Related Resources
